Catalent Inc (NYSE:CTLT) – Analysts at William Blair lifted their FY2018 earnings per share (EPS) estimates for shares of Catalent in a research report issued to clients and investors on Tuesday. William Blair analyst J. Kreger now anticipates that the company will post earnings of $1.53 per share for the year, up from their prior forecast of $1.52.
CTLT has been the topic of several other reports. Royal Bank of Canada set a $48.00 price target on shares of Catalent and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Goldman Sachs Group assumed coverage on shares of Catalent in a report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 price target on the stock. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Piper Jaffray Companies lifted their price target on shares of Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, November 7th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Catalent presently has a consensus rating of “Buy” and a consensus price target of $45.60.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The business had revenue of $606.30 million for the quarter, compared to analyst estimates of $565.05 million. During the same period in the previous year, the company earned $0.27 earnings per share. The business’s revenue for the quarter was up 25.3% on a year-over-year basis.
In other news, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were acquired at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. Insiders own 1.70% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. 361 Capital LLC lifted its position in Catalent by 18.6% during the third quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock valued at $2,795,000 after purchasing an additional 10,974 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Catalent by 25.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock valued at $41,773,000 after purchasing an additional 210,296 shares during the period. Sei Investments Co. lifted its position in Catalent by 119.1% during the third quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock valued at $3,761,000 after purchasing an additional 51,212 shares during the period. Stevens Capital Management LP acquired a new position in Catalent during the third quarter valued at $2,475,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in Catalent during the third quarter valued at $18,420,000. Institutional investors own 98.86% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.